Edwards Lifesciences Corp (EW)vsInogen Inc (INGN)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
INGN
Inogen Inc
$6.42
+1.58%
HEALTHCARE · Cap: $166.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1640% more annual revenue ($6.07B vs $348.67M). EW leads profitability with a 17.7% profit margin vs -6.5%. EW appears more attractively valued with a PEG of 2.14. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
INGN
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for INGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Earnings expanding 87.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
2.0% revenue growth
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -12.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : INGN
The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : INGN
The primary concerns for INGN are Revenue Growth, Market Cap, PEG Ratio.
Key Dynamics to Monitor
EW profiles as a mature stock while INGN is a turnaround play — different risk/reward profiles.
INGN carries more volatility with a beta of 1.78 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 49/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Inogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?